Iwamoto Noriyuki, Abe-Dohmae Sumiko, Lu Rui, Yokoyama Shinji
Biochemistry, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.
Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2282-7. doi: 10.1161/ATVBAHA.108.174714. Epub 2008 Oct 9.
Activator protein (AP) 2alpha negatively regulates expression of ABCA1 gene through Ser-phosphorylation of AP2alpha (Circ Res. 2007;101:156-165). Potential specific Ser-phosphorylation sites for this reaction were investigated in human AP2alpha.
The phosphorylation was shown mediated by PKD, and Ser258 and Ser326 were found in its specific phosphorylation sequence segment in AP2alpha. PKD phosphorylated Ser258 more than Ser326 and induced its binding to the ABCA1 promoter. These reactions and AP2alpha-induced suppression of the ABCA1 promoter activity were reversed by mutation of Ser258 more than Ser326 mutation. Knockdown of PKD by siRNA reduced the AP2alpha Ser-phosphorylation, and increased ABCA1 expression and HDL biogenesis. Gö6983 inhibited PKD more selectively than PKC in THP-1 and HEK 293 cells and in mice, and increased ABCA1 expression, HDL biogenesis, and plasma HDL level.
PKD phosphorylates AP2alpha to negatively regulate expression of ABCA1 gene to increase HDL biogenesis. The major functional phosphorylation of AP2alpha was identified at Ser258 by PKD, in the AP2alpha basic domain highly conserved among species and all 5 subtypes of AP2. PKD/AP2 system can be a potent pharmacological target for prevention of atherosclerosis.
激活蛋白(AP)2α通过AP2α的丝氨酸磷酸化负调控ABCA1基因的表达(《循环研究》。2007年;101:156 - 165)。在人AP2α中研究了该反应潜在的特异性丝氨酸磷酸化位点。
结果表明该磷酸化由蛋白激酶D(PKD)介导,并且在AP2α的特异性磷酸化序列片段中发现了Ser258和Ser326。PKD对Ser258的磷酸化作用强于Ser326,并诱导其与ABCA1启动子结合。与Ser326突变相比,Ser258突变对这些反应以及AP2α诱导的ABCA1启动子活性抑制作用的逆转更明显。用小干扰RNA(siRNA)敲低PKD可降低AP2α的丝氨酸磷酸化,增加ABCA1表达和高密度脂蛋白(HDL)的生成。在THP - 1细胞、人胚肾293细胞及小鼠中,Gö6983对PKD的抑制作用比蛋白激酶C(PKC)更具选择性,并且可增加ABCA1表达、HDL生成及血浆HDL水平。
PKD使AP2α磷酸化,从而负调控ABCA1基因的表达以增加HDL生成。在物种间及AP2的所有5个亚型中高度保守的AP2α碱性结构域中,PKD对AP2α的主要功能性磷酸化位点为Ser258。PKD/AP2系统可能是预防动脉粥样硬化的有效药理学靶点。